Semaglutide Market Hits Speed Bump with ₹100 Crore Excess Stock

The much-anticipated surge in the Indian semaglutide therapy market has encountered a significant hurdle as sluggish sales lead to a massive inventory overhang. Following an explosive start to the year, the weight-loss drug segment is now grappling with an estimated ₹100 crore in excess stock across the trade channel.

The Post-Patent Surge and Subsequent Slowdown

The obesity therapy market, valued at approximately ₹2,000 crore, experienced an unprecedented boom in April. This surge was triggered by the patent expiry of semaglutide on March 20, which paved the way for a flood of cheaper generic alternatives from major pharmaceutical players like Sun Pharma, Dr. Reddy's, and Torrent Pharmaceuticals. In April, the market saw a massive 50% month-on-month (m-o-m) increase in value and an 88% jump in volume.

However, this momentum evaporated quickly in May. According to data from market research firm Pharmarack, the market's value growth slowed to just 6% m-o-m, while unit growth decelerated to 12%. This sudden deceleration has left distributors and wholesalers in a precarious position.

Inventory Overhang and Channel Stagnation

The imbalance between supply and demand has resulted in a significant "inventory overhang." Rajiv Singhal, General Secretary of the All India Organisation of Chemists and Druggists (AIOCD), noted that stockists and wholesalers are currently holding 50–60 days of GLP-1 (semaglutide) inventory. This is substantially higher than the industry standard of 30–45 days.

Due to this buildup, channel partners have effectively hit the pause button on fresh procurement. Most wholesalers have stopped ordering new supplies from pharmaceutical manufacturers until the existing ₹100 crore worth of stock is liquidated from the system.

Regulatory Shifts and Competitive Landscape

Industry experts suggest that the cooling demand may not be purely organic. The slowdown coincides with recent government advisories and stricter prescribing guidelines. Following guidelines announced in April, GLP-1 therapies—which are used to manage both type 2 diabetes and obesity—must now be prescribed exclusively by qualified specialists, potentially limiting easy access for general patients.

Despite the semaglutide volatility, the broader pharma landscape remains resilient. Eli Lilly's Mounjaro (tirzepatide), another GLP-1 receptor agonist, remains a market leader. Mounjaro's sales rose by 12% to reach ₹136 crore in May. This contributed to the overall growth of India’s ₹2.5 lakh crore organized pharma retail market, which grew by nearly 11% during the month, driven largely by chronic therapies.

Key Takeaways

  • Massive Inventory Glut: The semaglutide trade channel is currently saddled with approximately ₹100 crore in excess stock, with wholesalers holding up to 60 days of inventory.
  • Growth Deceleration: After a 50% value surge in April following patent expiry, May saw month-on-month value growth plummet to just 6%.
  • Regulatory Impact: Stricter guidelines requiring specialist-only prescriptions for GLP-1 therapies are believed to be a contributing factor to the sudden moderation in sales.